Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortization of Deferred Charges (2021 - 2022)

SAB Biotherapeutics (SABS) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $24717.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Amortization of Deferred Charges fell 40.09% year-over-year to $24717.0, compared with a TTM value of $138939.0 through Sep 2022, changed N/A, and an annual FY2021 reading of $164983.0, changed 0.03% over the prior year.
  • Amortization of Deferred Charges was $24717.0 for Q3 2022 at SAB Biotherapeutics, down from $31809.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $41259.0 in Q1 2021 and bottomed at $24717.0 in Q3 2022.